(VIANEWS) – New Oriental Education & Technology Group Sponsored ADR representing 1 Ordinary Share (EDU), Catalyst Pharmaceuticals (CPRX), United Therapeutics Corporation (UTHR) are the highest sales growth and return on equity stocks on this list.
Here is a list of stocks with an above 5% expected next quarter sales growth, and a 3% or higher return on equity. May these stocks be a good medium-term investment option?
1. New Oriental Education & Technology Group Sponsored ADR representing 1 Ordinary Share (EDU)
28.4% sales growth and 8.27% return on equity
New Oriental Education & Technology Group Inc. provides private educational services under the New Oriental brand in the People's Republic of China. It operates through K-12 AST, Test Preparation and Other Courses; and Others segments. The company offers test preparation courses to students taking language and entrance exams used by educational institutions in the United States, the People's Republic of China, and the Commonwealth countries; and after-school tutoring courses for middle and high school students to enhance their exam scores, as well as for children to teach English. It also provides language training courses, including English, as well as other foreign languages, such as German, Japanese, French, Korean, Italian, and Spanish; operates a full-time private primary and secondary school in Yangzhou seeking a full curriculum with a focus on English; develops and edits educational materials for language training and test preparation; and offers online education programs that include college, K-12, and pre-school education. In addition, the company offers overseas studies consulting and overseas study tour services. As of May 31, 2020, it offered educational programs, services, and products to students through a network of 104 schools, 1,361 learning centers, and 12 bookstores. The company was founded in 1993 and is headquartered in Beijing, the People's Republic of China.
Earnings Per Share
As for profitability, New Oriental Education & Technology Group Sponsored ADR representing 1 Ordinary Share has a trailing twelve months EPS of $1.8.
PE Ratio
New Oriental Education & Technology Group Sponsored ADR representing 1 Ordinary Share has a trailing twelve months price to earnings ratio of 38.11. Meaning, the purchaser of the share is investing $38.11 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 8.27%.
Growth Estimates Quarters
The company’s growth estimates for the current quarter and the next is 37.2% and 31%, respectively.
Volume
Today’s last reported volume for New Oriental Education & Technology Group Sponsored ADR representing 1 Ordinary Share is 2302670 which is 30.78% above its average volume of 1760700.
2. Catalyst Pharmaceuticals (CPRX)
20.4% sales growth and 14.55% return on equity
Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients. The company develops Firdapse for the treatment of MuSK antibody positive myasthenia gravis and spinal muscular atrophy type. It has license agreements with BioMarin Pharmaceutical Inc.; and collaboration and license agreement with Endo Ventures Limited for the development and commercialization of generic Sabril tablets. The company was founded in 2002 and is based in Coral Gables, Florida.
Earnings Per Share
As for profitability, Catalyst Pharmaceuticals has a trailing twelve months EPS of $0.63.
PE Ratio
Catalyst Pharmaceuticals has a trailing twelve months price to earnings ratio of 24.16. Meaning, the purchaser of the share is investing $24.16 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 14.55%.
Yearly Top and Bottom Value
Catalyst Pharmaceuticals’s stock is valued at $15.22 at 20:22 EST, way under its 52-week high of $17.99 and way higher than its 52-week low of $11.55.
Moving Average
Catalyst Pharmaceuticals’s worth is under its 50-day moving average of $16.09 and higher than its 200-day moving average of $15.10.
Volume
Today’s last reported volume for Catalyst Pharmaceuticals is 817840 which is 36.47% below its average volume of 1287390.
3. United Therapeutics Corporation (UTHR)
17% sales growth and 20.08% return on equity
United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. Its commercial therapies include Remodulin, an infused formulation of the prostacyclin analogue treprostinil for subcutaneous and intravenous administration to diminish symptoms associated with exercise in pulmonary arterial hypertension (PAH) patients; Tyvaso, an inhaled formulation of treprostinil to enhance the exercise ability in PAH patients; Orenitram, a tablet dosage form of treprostinil to enhance the exercise capacity in PAH patients; Unituxin, a monoclonal antibody for treating high-risk neuroblastoma; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients. The company also engages in developing OreniPro, RemoPro, Tyvaso DPI, Trevyent, Ralinepag, and Aurora-GT to treat PAH; Unexisome to treat bronchopulmonary dysplasia; and the research and development of various organ transplantation-related technologies, including regenerative medicine, xenotransplantation, and ex-vivo lung perfusion, as well as the development of medicine for other diseases. It has licensing and collaboration agreements with Medtronic, Inc. to develop and commercialize the implantable system for Remodulin; Caremark, L.L.C. to provide refills of implanted pumps at its infusion centers; DEKA Research & Development Corp. to develop a semi-disposable system for the subcutaneous delivery of Remodulin; MannKind Corporation to develop and license treprostinil inhalation powder and Dreamboat devices; and Arena Pharmaceuticals, Inc. to develop ralinepag for the treatment of PAH. The company was incorporated in 1996 and is headquartered in Silver Spring, Maryland.
Earnings Per Share
As for profitability, United Therapeutics Corporation has a trailing twelve months EPS of $21.12.
PE Ratio
United Therapeutics Corporation has a trailing twelve months price to earnings ratio of 15.98. Meaning, the purchaser of the share is investing $15.98 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 20.08%.
Yearly Top and Bottom Value
United Therapeutics Corporation’s stock is valued at $337.54 at 20:22 EST, under its 52-week high of $343.98 and way higher than its 52-week low of $208.62.
4. Surgery Partners (SGRY)
13.6% sales growth and 4.76% return on equity
Surgery Partners, Inc., through its subsidiaries, owns and operates a network of surgical facilities and ancillary services in the United States. The company operates through two segments, Surgical Facility Services and Ancillary Services. Its surgical facilities comprise ambulatory surgery centers and surgical hospitals that offer non-emergency surgical procedures in various specialties, including gastroenterology, general surgery, ophthalmology, orthopedics, and pain management. The company's surgical hospitals also provide ancillary services, such as diagnostic imaging, pharmacy, laboratory, obstetrics, oncology, physical therapy, and wound care; and ancillary services, which consist of multi-specialty physician practices, urgent care facilities, and anesthesia services. As of December 31, 2021, it owned or operated a portfolio of 126 surgical facilities, including 108 ambulatory surgical centers and 18 surgical hospitals in 31 states. Surgery Partners, Inc. was founded in 2004 and is headquartered in Brentwood, Tennessee.
Earnings Per Share
As for profitability, Surgery Partners has a trailing twelve months EPS of $0.01.
PE Ratio
Surgery Partners has a trailing twelve months price to earnings ratio of 2907. Meaning, the purchaser of the share is investing $2907 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 4.76%.
Revenue Growth
Year-on-year quarterly revenue growth grew by 7.7%, now sitting on 2.79B for the twelve trailing months.
Previous days news about Surgery Partners(SGRY)
- Surgery partners (sgry) meets Q2 earnings estimates. According to Zacks on Tuesday, 6 August, "While Surgery Partners has underperformed the market so far this year, the question that comes to investors’ minds is: what’s next for the stock?"
5. RLI Corp. (RLI)
13.4% sales growth and 23.02% return on equity
RLI Corp., an insurance holding company, underwrites property and casualty insurance. Its Casualty segment provides commercial and personal coverage products; and general liability products, such as coverage for third-party liability of commercial insureds, including manufacturers, contractors, apartments, and mercantile. It also offers coverages for security guards and environmental liability for underground storage tanks, contractors and asbestos, and environmental remediation specialists; and professional liability coverages for errors and omission coverage for small to medium-sized design, technical, computer, and miscellaneous professionals. This segment provides commercial automobile liability and physical damage insurance to local, intermediate and long haul truckers, public transportation entities, and other types of specialty commercial automobile risks; incidental and related insurance coverages; inland marine coverages; management liability coverages, such as directors and officers liability insurance, fiduciary liability and coverages, employment practice liability, and for various classes of risks, including public and private businesses; and home business insurance products. The company's Property segment offers commercial property, cargo, hull, protection and indemnity, marine liability, inland marine, homeowners' and dwelling fire, and other property insurance products. Its Surety segment offers commercial surety bonds for medium to large-sized businesses; small bonds for businesses and individuals; and bonds for small to medium-sized contractors. The company also engages in various reinsurance coverages. It markets its products through branch offices, wholesale and retail brokers, carrier partners, and underwriting and independent agents. RLI Corp. was incorporated in 1965 and is headquartered in Peoria, Illinois.
Earnings Per Share
As for profitability, RLI Corp. has a trailing twelve months EPS of $7.23.
PE Ratio
RLI Corp. has a trailing twelve months price to earnings ratio of 19.73. Meaning, the purchaser of the share is investing $19.73 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 23.02%.
